CA 125

CA 125CA 125

CA 125

Method of Collection:

Volume as mentioned on gel vacutainer (Yellow)

Days for reporting:

Same Day


Interpretation :-

* Enzymun -Test CA-125 (electrochemiluminescence immunoassay,

CA 125 is found in a high percentage of non-mucinous ovarian tumours of epithelial origin and can be
detected in serum. CA 125 does not occur on the surface epithelium of normal ovaries (adult and fetal).
Exceptions are inclusion cysts, metaplasia and papillary neoplasia.

CA 125 has been found in the amnion and in the coelomic epithelium; both of these tissues are of fetal
origin. In tissues of adult origin, the presence of CA 125 has been demonstrated in the epithelium of
the oviduct, in the endometrium and in the endocervix.

Clearly elevated values are sometimes found in various benign gynecological tumours.

Slight elevations of this marker are also found in early pregnancy, various autoimmune diseases,
hepatitis, chronic pancreatitis and liver cirrhosis

CA 125 is today the most important tumour marker for monitoring the therapy and progress of patients
with serous ovarian. Ovarian carcinoma accounts for about 20% of gynecological tumours; the incidence
is 15/100,000.

Among the malignant tumours, CA 125 elevations are also found in breast cancer and bronchial carcinoma.
At a cutoff value of 65 U/ml; CA 125 has an overall sensitivity of 87%(serous ovarian carcinoma 92%,
mucinous ovarian carcinoma 64%, endometrial carcinoma 89%).
The sensitivity is dependent on the stage of the disease:FIGO I 66%,FIGO II 74% FIGO III 94%,
FIGO IV 100% (Cutoff value 65 U/ml).

FIGO = Federation of Gynecology and Obstetrics.
At a cutoff value of 35 U/ml, the overall sensitivity is over 90%.


Why is the Test Done?

CA-125 is primarily used to monitor therapy during treatment for ovarian cancer. CA-125 is also used to detect whether cancer has come back after treatment is complete. A series of CA-125 tests that shows rising or falling concentrations is often more useful than a single result. CA-125 is sometimes used to test and monitor high-risk women who have a family history of ovarian cancer but who do not yet have the disease. The test is not used, however, to screen women for ovarian cancer because it is non-specific. In some cases, a CA-125 is done in woman with a pelvic mass in order to help determine the cause. A transvaginal ultrasound may be done along with this If CA-125 levels fall during therapy, this generally indicates that the cancer is responding to treatment. If CA-125 levels rise or stay the same, then the cancer may not be responding to therapy. High CA-125 levels after treatment is complete may indicate that the cancer has come back. If a woman who has been diagnosed with ovarian cancer has a baseline CA-125 level that is normal, then the test is not likely to be useful to monitor her ovarian cancer. In this case, the ovarian cancer may not be producing CA-125 and is not a good marker of disease progression. In a woman with a pelvic mass, and in a woman with a high risk for developing ovarian cancer, a significantly elevated CA-125 is a concern but does not necessarily indicate ovarian cancer. This finding would prompt further testing and evaluation. Because CA-125 can be high in many normal or benign conditions, such as pregnancy, menstruation, endometriosis, and pelvic inflammatory disease, it is not useful or recommended as a screening test for the general population.


How to prepare for the Test:

+91 81304 15737